Clinical Trials
1495
88 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1817
Terminated
117
7.8%
Recruiting
149
10.0%
Available
1
0.1%
Withdrawn
55
3.7%
Active, not recruiting
46
3.1%
Unknown
4
0.3%
Completed
1081
72.3%
Enrolling By Invitation
20
1.3%
Not yet recruiting
22
1.5%
No approval data available
- Royalty Pharma has donated $7.5 million to Blood Cancer United's Therapy Acceleration Program, becoming the first and largest corporate donor under an updated funding model. - TAP deploys donations as venture capital investments in early-stage biotech companies, reinvesting financial returns to fund future blood cancer therapy development. - The program has supported six therapies that reached FDA approval or National Comprehensive Cancer Network guidelines, with more than 30 active clinical studies underway. - Blood Cancer UK contributed $1 million and Blood Cancer United committed $15 million as inaugural funders of TAP's next phase.
- The NIH has awarded a first installment of $4.6 million, part of up to $12.8 million over three years, to a multi-university team modeling drug-hormone interactions in women. - Thirteen researchers from Michigan State, Rutgers, Emory, Tulane, and other institutions will build computational models integrating age and reproductive cycle stage into drug predictions. - The project targets metabolic drugs such as metformin, insulin, and GLP-1 agents, whose effects may vary with shifting female hormone levels. - All computer models and data will be freely available worldwide, with findings intended to inform NIH guidelines and national safety standards.
- Canada announced the hiring of 64 scholars supported by more than C$500 million ($350 million) over eight years through its Global Impact+ Research Talent Initiative. - Forty-eight of the recruited academics come from US institutions including Harvard, Cornell, and MIT, spanning medicine, engineering, and climate science. - Researchers cited frozen federal grants and concerns over academic freedom under the Trump administration as key factors driving their departure. - The initiative is part of a C$1.7 billion ($1.2 billion) effort to attract world-leading researchers to Canadian universities.
- Weekly counts of U.S. children filling a leucovorin prescription rose from 734 to 5,858 across 2025, a roughly 700% increase, according to a NEJM analysis. - A 46% single-week jump in pediatric dispensing coincided with a September 2025 federal press conference promoting leucovorin for autism. - The FDA approved leucovorin in March 2026 only for cerebral folate transport deficiency tied to a FOLR1 gene variant, not for autism spectrum disorder. - The largest randomized trial supporting leucovorin in autism was retracted after a statistical review could not replicate its results, leaving effectiveness and long-term safety uncertain.
- AI is forcing medical schools to rapidly reconsider physician training, with educators describing this as a "key inflection point for medical education," according to NYU's Marc Triola. - New AI tools enable personalized assessment of trainees' communication and clinical reasoning skills, areas that have long been difficult to evaluate directly. - Concerns about "never-skilling" and "deskilling" arise as trainees offload cognitive tasks to AI, though some experts argue not all deskilling is harmful and may free capacity for essential skills. - Medical education leaders emphasize the need for adaptive training models that partner with learners, as the evidence base on AI's educational effects remains surprisingly limited.
- A University of Michigan study found only 12% of men prescribed testosterone received guideline-concordant diagnostic testing before their initial prescription. - The retrospective review of 200 patients at Michigan Medicine revealed that more than half had contraindications such as obstructive sleep apnea or prostate cancer. - Primary care physicians wrote 45% of prescriptions, urologists 35.5%, and endocrinologists 18%, with topical formulations being the most common at 68.5%. - Researchers call for quality-improvement efforts and clinical decision support tools to promote consistent, guideline-concordant testosterone prescribing.
- Continuity Biosciences has launched a Phase I clinical trial evaluating gemcitabine delivered via its iontophoretic oncology platform (IOP) for pancreatic cancer treatment. - The proprietary IOP platform aims to enable localized, controlled delivery of therapeutics directly into pancreatic tumors while minimizing systemic toxicity. - The study is now enrolling patients at leading academic medical centers including West Virginia University and University of Michigan. - Pancreatic cancer remains one of the leading causes of cancer-related mortality with five-year survival rates in the low double digits.
- The phase 4 PASSAGE study demonstrated that tezepelumab reduced asthma exacerbations by 70% across diverse patient populations typically excluded from clinical trials. - Significant improvements were observed in Black patients, adolescents, smokers, and patients with asthma-COPD overlap, addressing critical gaps in severe asthma treatment evidence. - The study enrolled 286 patients and showed clinically meaningful improvements in lung function, asthma control, and quality of life alongside a 50% reduction in systemic corticosteroid use.
- Prescriptions for ivermectin and fenbendazole among cancer patients rose 2.5-fold in early 2025 following Mel Gibson's claims on The Joe Rogan Experience, according to a JAMA Network Open study. - Researchers analyzed health records from over 68 million patients and found the steepest increases among white men and patients in the South, groups overlapping with Rogan's audience. - No human clinical trials have demonstrated that ivermectin or fenbendazole are safe or effective for treating cancer, and experts warn patients may forgo proven therapies. - The findings highlight the growing challenge of celebrity-driven health misinformation in an era where half of U.S. adults under 50 get health information from influencers.
- UCLA researchers led by Professor Keriann Backus have developed SEE-CITE, a new technology that makes light-activated protein labeling more precise and reliable for drug discovery applications. - The technology enables direct comparison of how different molecules compete for the same protein binding site in a single experiment, addressing longstanding challenges with photo-crosslinking methods. - As proof of concept, the team analyzed cancer drugs dasatinib and ascinimib, revealing that the newer drug ascinimib showed fewer off-target kinase interactions. - SEE-CITE has potential applications in drug discovery for cancer, cholesterol regulation, and metabolic liver disorders by providing more accurate protein-drug interaction mapping.
